Patents by Inventor John W. M. Mackinnon
John W. M. Mackinnon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5103020Abstract: A method for the preparation of 3-(2-aminoethyl)-N-methyl-1H-indole-5-methanesulphonamide by reaction of 4-hydrazino-N-methylbenzenemethanesulphonamide and 4-chloro-1-hydroxybutanesulphonic acid, sodium salt in the presence of an acid.Type: GrantFiled: June 20, 1991Date of Patent: April 7, 1992Assignee: Glaxo Group LimitedInventors: Frederick D. Albinson, John W. M. MacKinnon, Derek L. Crookes
-
Patent number: 4777179Abstract: The invention provides compounds of the general formula ##STR1## and physiologically acceptable salts and hydrates thereof, in which one of R.sub.1 and R.sub.2 represents hydrogen, halogen or a C.sub.1-4 alkyl group which may be optionally substituted by hydroxy or C.sub.1-4 alkoxy, and the other represents the group R.sub.4 R.sub.5 NAlk-- in which Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms;R.sub.3, which may be in either the 2 or 3-position, represents the ##STR2## where X represents --CH.sub.2 --, --O-- or --S--; n represents zero, 1 or 2;m represents 2, 3 or 4; andR.sub.7 represents hydrogen, alkyl, alkenyl, aralkyl, or C.sub.2-6 alkyl substituted by hydroxy or alkoxy; andR.sub.8 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl, acyloxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkyloxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxy or alkoxy, or the group NR.sub.10 R.sub.11 ; with the provisos thatwhere R.sub.2 represents the group R.sub.4 R.sub.Type: GrantFiled: October 21, 1985Date of Patent: October 11, 1988Assignee: Glaxo Group LimitedInventors: John Bradshaw, Duncan B. Judd, Barry J. Price, John W. Clitherow, John W. M. Mackinnon, Linda Carey, Roger Hayes
-
Patent number: 4764612Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the variables are as defined in the specification.The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.Also disclosed are intermediates in the preparation of the compounds of the formula (I).Type: GrantFiled: February 6, 1986Date of Patent: August 16, 1988Assignee: Glaxo Group LimitedInventors: John W. Clitherow, John Bradshaw, John W. M. Mackinnon, Barry J. Price, Michael Martin-Smith, Duncan B. Judd
-
Patent number: 4670448Abstract: The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the substituents are defined in the detailed description.The compounds show pharmaceutical activity as selective histamine H.sub.2 -antagonists.Type: GrantFiled: February 10, 1983Date of Patent: June 2, 1987Assignee: Glaxo Group LimitedInventors: John W. Clitherow, John Bradshaw, John W. M. Mackinnon, Duncan B. Judd, David E. Bays, Roger Hayes, Andrew Pearce
-
Patent number: 4571394Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichQ represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4- positions:Z represents one of the groups ##STR2## where X represents NCN, NSO.sub.2 Methyl, NSO.sub.2 Phenyl or CHNO.sub.2. The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.Type: GrantFiled: July 23, 1982Date of Patent: February 18, 1986Assignee: Glaxo Group LimitedInventors: Roger Hayes, David E. Bays, John W. M. MacKinnon
-
Patent number: 4536508Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, which show pharmacological activity as selective histamine H.sub.2 -antagonists.Type: GrantFiled: February 18, 1983Date of Patent: August 20, 1985Assignee: Glaxo Group LimitedInventors: John W. Clitherow, Barry J. Price, John Bradshaw, Michael Martin-Smith, John W. M. Mackinnon, Duncan B. Judd, Roger Hayes
-
Patent number: 4518598Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, and hydrates thereof. The substituents are defined in the specification.The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.Type: GrantFiled: January 9, 1984Date of Patent: May 21, 1985Assignee: Glaxo Group LimitedInventors: Roger Hayes, David E. Bays, John W. M. Mackinnon, Linda Carey, Philip Blatcher
-
Patent number: 4507296Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts or hydrates thereof, in which the substituents are defined later in the specification.The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.Type: GrantFiled: January 9, 1984Date of Patent: March 26, 1985Assignee: Glaxo Group LimitedInventors: Roger Hayes, David E. Bays, John W. M. Mackinnon, Linda Carey
-
Patent number: 4442110Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen, C.sub.1-10 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkylamino or cycloalkyl, or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered alicyclic heterocyclic ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom;Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms;Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, the furan ring optionally bearing a further substituent R.sub.Type: GrantFiled: November 24, 1981Date of Patent: April 10, 1984Assignee: Glaxo Group LimitedInventors: John W. Clitherow, John Bradshaw, John W. M. Mackinnon, Barry J. Price, Michael Martin-Smith, Duncan B. Judd
-
Patent number: 4410523Abstract: The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen, C.sub.1-10 alkyl, cycloalkyl, alkenyl, aralkyl, trifluoroalkyl, heteroaralkyl, or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkyamino or cycloalkyl, or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups, or a hydroxy group and/or may contain another heteroatom selected from oxygen and sulphur;Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms and is attached to the cyclohexadiene ring at either the 4- or 5- position;X represents --CH.sub.2 or --O--;m represents 2, 3, 4 or 5 and when X is --O-- the chain (CH.sub.2).sub.Type: GrantFiled: October 22, 1980Date of Patent: October 18, 1983Assignee: Glaxo Group LimitedInventors: William D. Ollis, Barry J. Price, Linda Carey, Roger Hayes, John W. Clitherow, John Bradshaw, John W. M. Mackinnon
-
Patent number: 4323566Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2, which may be the same of different, each represent hydrogen, C.sub.1 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl, or alkyl substituted by hydroxy, alkoxy, amino alkylamino dialkylamino or cycloalkyl or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom which is oxygen or sulphur;Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms,Q represents a furan or thiophene ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5- positions, the furan ring optionally bearing a further substituent R.sub.Type: GrantFiled: February 29, 1980Date of Patent: April 6, 1982Assignee: Glaxo Group LimitedInventors: John W. Clitherow, Barry J. Price, John Bradshaw, Michael Martin-Smith, John W. M. MacKinnon, Duncan B. Judd, Linda Carey
-
Patent number: 4318913Abstract: The invention relates to compounds of the formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2 represent hydrogen, an aliphatic or cycloaliphatic group, or R.sub.1 and R.sub.2 together with the nitrogen atom form a 5 to 10 membered heterocyclic ring:Alk represents a straight or branched alkylene chain;Q represents furan, thiophen or benzene ring which is incorporated into the rest of the molecule;X represents --CH.sub.2 --, ##STR2## --O-- or --S-- whereR.sub.6 represents hydrogen or methyl;n represents zero, 1 or 2;m represents 2, 3 or 4;R.sub.3 represents hydrogen, a substituted or unsubstituted aliphatic or aryl group and;R.sub.4 and R.sub.5, which may be the same or different, each represent hydrogen, a substituted or unsubstituted aliphatic, aryl, or together with the nitrogen atom form a heterocyclic group.Type: GrantFiled: April 26, 1979Date of Patent: March 9, 1982Assignee: Glaxo Group LimitedInventors: John W. Clitherow, John Bradshaw, John W. M. Mackinnon, Barry J. Price, Michael Martin-Smith, Duncan B. Judd